Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

NCT07520006 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: NX-5948
DRUG: venetoclax
DRUG: rituximab
DRUG: obinutuzumab

Sponsor

Nurix Therapeutics, Inc.